Skip to content

ResMed RMD Q3 2025 earnings

Reported April 23, 2025 · After market close

Revenue estimate$1.3B
EPS estimate$2.38

Next report

Aug 6, 2026 (In 3 weeks)
Revenue estimate$1.5B
EPS estimate$2.90

Financials

Q3 2025

Income statement

See full
Revenue$1.3B+7.9%
Gross profit$766.4M+10.6%
Operating income$426.3M+13.8%
Net income$365.0M+21.5%
EPS (diluted)$2.48+21.6%

Balance sheet

See full
Cash & equivalents$932.7M+292%
Total debt$849.7M-27.8%
Total equity$5.5B+19.8%
Total assets$7.6B+11.0%

Cash flow

See full
Operating cash flow$578.7M+43.9%
CapEx$20.8M-1.9%
Free cash flow$557.9M+46.5%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$32.88B+13.0%
Enterprise value$32.79B+9.2%
P/E25×-5.3×
P/S6.5×+0.2×

Profitability

See full
Gross margin58.8%+3.0pp
Operating margin32.1%+5.6pp
Net margin26.2%+5.2pp
FCF margin31.2%+7.5pp

Returns & leverage

See full
Return on equity25.8%+3.4pp
Debt / equity0.2×-0.1×
Current ratio3.4×+0.4×

Segments

By product

See full
Devices$1.4B+6.0%
Sleep And Breathing Health$1.1B+7.8%
Masks and other$908.7M+10.6%
Residential Care Software$161.2M+8.9%

By geography

See full
Global revenue$1.3B+7.9%
U.S., Canada and Latin America$749.3M+9.0%
Combined Europe, Asia and other markets$381.3M+5.5%

By segment

See full
Sleep and Breathing Health$1.1B+7.8%
Residential Care Software$161.2M+8.9%

Versus estimates

Ask the moment ResMed reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did ResMed report Q3 2025 earnings?
ResMed (RMD) reported Q3 2025 earnings on April 23, 2025 after market close.
What were ResMed's Q3 2025 revenue and EPS?
ResMed reported revenue of $1.3B and diluted EPS of $2.37 for Q3 2025.
Did ResMed beat estimates in Q3 2025?
Revenue beat the consensus estimate of $1.3B by $3.6M. EPS missed the consensus estimate of $2.38 by $0.01.
How did ResMed's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 7.9% from $1.2B a year earlier and diluted EPS grew 11.3% from $2.13.
Where can I find ResMed's Q3 2025 SEC filings?
You can read the 10-Q periodic report (0000943819-25-000008) directly on SEC EDGAR. The filing index links above go to sec.gov.